NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $14.20 -0.30 (-2.07%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$13.95▼$14.7450-Day Range$12.72▼$16.0352-Week Range$9.67▼$18.07Volume466,009 shsAverage Volume912,120 shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$35.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Day One Biopharmaceuticals alerts: Email Address Day One Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside151.5% Upside$35.71 Price TargetShort InterestBearish22.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 2 Articles This WeekInsider TradingSelling Shares$714,572 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.68) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector523rd out of 910 stocksPharmaceutical Preparations Industry240th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Day One Biopharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.94% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently increased by 11.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 2.2 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $714,572.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($1.68) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -5.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesAugust 20, 2024 | insidertrades.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 2,232 Shares of StockSeptember 1, 2024 | americanbankingnews.comShort Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Grows By 11.1%September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 18, 2024 | finance.yahoo.comDAWN Sep 2024 12.500 call (DAWN240920C00012500)August 17, 2024 | finance.yahoo.comA great week that adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) one-year returns, institutional investors who own 56% must be happyAugust 14, 2024 | investorplace.comBank of America Says Buy These 3 Stocks for a Double-Digit RallyAugust 4, 2024 | nasdaq.comDay One Biopharmaceuticals Breaks Below 200-Day Moving Average - Notable for DAWNAugust 1, 2024 | msn.comB of A Securities Upgrades Day One Biopharmaceuticals (DAWN)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.July 31, 2024 | markets.businessinsider.comBuy Rating Affirmed on Day One Biopharmaceuticals Following Ojemda’s Successful Launch and Strategic Focus on DAY301 DevelopmentJuly 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Ojemda Sales and Promising Clinical TrialsJuly 30, 2024 | msn.comDay One Biopharmaceuticals GAAP EPS of -$0.05, revenue of $8.19MJuly 30, 2024 | globenewswire.comDay One Reports Second Quarter 2024 Financial Results and Corporate ProgressJuly 30, 2024 | globenewswire.comDay One Announces Oversubscribed $175.0 Million Private PlacementJuly 26, 2024 | markets.businessinsider.comDay One Biopharmaceuticals Poised for Growth with Strategic Partnerships and Promising Ojemda ProspectsJuly 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Day One Biopharmaceuticals (DAWN)July 25, 2024 | markets.businessinsider.comIpsen Posts Higher H1 Profit, Signs New Partnership With Day One For TovorafenibJuly 25, 2024 | globenewswire.comIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumorSee More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$35.71 High Stock Price Target$44.00 Low Stock Price Target$24.00 Potential Upside/Downside+151.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax Margin-2,025.49% Return on Equity-50.01% Return on Assets-44.15% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual Sales$8.19 million Price / Sales151.48 Cash FlowN/A Price / Cash FlowN/A Book Value$3.50 per share Price / Book4.06Miscellaneous Outstanding Shares87,390,000Free Float80,049,000Market Cap$1.24 billion OptionableOptionable Beta-1.51 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer Dr. Elly Barry M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTCastle BiosciencesNASDAQ:CSTLMannKindNASDAQ:MNKDLeMaitre VascularNASDAQ:LMATBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsRegency Capital Management Inc. DESold 1,000 shares on 8/21/2024Ownership: 0.011%Point72 Asset Management L.P.Bought 470,247 shares on 8/19/2024Ownership: 0.538%Samuel C BlackmanSold 2,232 sharesTotal: $31,248.00 ($14.00/share)Driehaus Capital Management LLCSold 12,565 shares on 8/16/2024Ownership: 0.808%Charles N York IISold 2,633 sharesTotal: $36,862.00 ($14.00/share)View All Insider TransactionsView All Institutional Transactions DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of 2024. Since then, DAWN shares have decreased by 2.7% and is now trading at $14.20. View the best growth stocks for 2024 here. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced its quarterly earnings results on Tuesday, July, 30th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Top institutional shareholders of Day One Biopharmaceuticals include Deerfield Management Company L.P. Series C (3.34%), Maverick Capital Ltd. (1.39%), Dimensional Fund Advisors LP (1.02%) and Driehaus Capital Management LLC (0.81%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Michael Gladstone, Papanek Julie Grant, Julie Papanek Grant, Charles N York II, Jeremy Bender and Pharmaceutical Co Ltd Takeda. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DAWN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
